To compare the impact of 18F-sodium-fluoride (NaF) PET/CT, 18F-fluorocholine (FCH) PET/CT and diffusion-weighted whole-body MRI (DW-MRI) on the management of patients with prostate cancer (PCa) suspicious for distant metastasis.
Prostate cancer patients were prospectively included between December 2011 and August 2014 and benefited from these three whole-body imaging (WBI) modalities within 1 month in addition to the standard PCa workup. Management was prospectively decided by clinicians during two multidisciplinary meetings, before and after the whole-body imaging workup. Rates of induced changes of whole-body imaging modalities were compared by Cochran's Q test.
One-hundred-one patients (27 at staging, 59 at first biochemical recurrence (BCR) and 15 at first episode of rising serum level of prostate-specific antigen during androgen-deprivation therapy) were included. The overall rate of management changes was 52%: 29% as a consequence of WBI, higher for FCH-PET/CT than for NaF-PET/CT or DW-MRI (p < 0.0001) and highest (41%) for FCH-PET/CT at BCR. Actual management was adequate in all patients but two.
Whole-body imaging induced a change in management in approximately a third of PCa patients suspicious for metastasis. The impact rate was determined to be greatest at first BCR using FCH-PET/CT. NaF-PET/CT and DW-MRI seemed less useful in this context.
World journal of urology. 2018 Oct 31 [Epub ahead of print]
Mathieu Gauthé, Cyrielle Aveline, Frédéric Lecouvet, Laure Michaud, Caroline Rousseau, Marc Tassart, Olivier Cussenot, Jean-Noël Talbot, Isabelle Durand-Zaleski
Department of Nuclear Medicine, Hôpital Tenon, Assistance Publique Hôpitaux de Paris (AP-HP), Sorbonne Université, 4 rue de la Chine, 75020, Paris, France. ., Department of Nuclear Medicine, Hôpital Tenon, Assistance Publique Hôpitaux de Paris (AP-HP), Sorbonne Université, 4 rue de la Chine, 75020, Paris, France., Department of Radiology, Centre du Cancer, Institut de Recherche Expérimentale Et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium., Nuclear Medicine Unit, ICO Gauducheau Cancer Centre, Saint-Herblain, France., Department of Radiology, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France., Department of Urology, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France., AP-HP Health Economics Research Unit, INSERM UMR 1123, Paris, France.